Sanofi And GSK’s Much-Delayed COVID-19 Vaccine Ready To File, But Role Looks Limited
Solid Data But No Advantages Over mRNA Jabs
Tipped as one of the most likely to succeed back in early 2020, the delayed development of the adjuvanted protein-based COVID-19 vaccine been humbling for both companies.
You may also be interested in...
Phase III data from two studies of the adjuvanted recombinant vaccine candidate showed increases in neutralizing antibody titers against the original SARS-CoV-2 strain and variants of concern.
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.